Trial Profile
Double-Blinded, Double-Dummy, Study Comparing Salmeterol/fluticasone propionate to Placebo in Patients With COPD and Associated Poor Sleep or Daytime Somnolence.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 22 Mar 2011 Results presented at the 67th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 17 May 2010 Results presented at 106th International Conference of the American Thoracic Society.
- 17 May 2010 New trial record